Neutralization of Clostridium difficile toxin A using antibody combinations

mAbs

Volumn 2, Issue 2, 2010, Pages 190-198

  Demarest, Stephen J ^a,c   Hariharan, Mangala ^a   Elia, Marikka ^a   Salbato, Jared ^a   Jin, Ping ^a   Bird, Colin ^b   Short, Jay M ^a   Kimmel, Bruce E ^a   Dudley, Michael ^a   Woodnutt, Gary ^a   Hansen, Geneviève ^a  

^a BIOGEN   (United States)

^b JEALOTT S HILL INTERNATIONAL RESEARCH CENTRE   (United Kingdom)

^c DIVERSA CORPORATION   (United States)

Author keywords

Cell wall binding domains; Clostridium difficile; CROPs; mAb combination; Repeat proteins; Therapeutic antibody; Toxin neutralization

Indexed keywords

CLOSTRIDIUM DIFFICILE TOXIN A; NEUTRALIZING ANTIBODY;

ARTICLE; CELL CULTURE; CELL SURFACE; CELL WALL; CLOSTRIDIUM DIFFICILE; EPITHELIUM CELL; HUMAN; NONHUMAN;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTITOXINS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BINDING SITES, ANTIBODY; CHO CELLS; CLOSTRIDIUM DIFFICILE; CRICETINAE; CRICETULUS; DIARRHEA; DRUG COMBINATIONS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; EPITOPE MAPPING; HUMANS; MICE; PROTEIN BINDING;

EID: 77953680927     PISSN: 19420862     EISSN: None     Source Type: Journal    
DOI: 10.4161/mabs.2.2.11220     Document Type: Article

References (51)

1. Kyne L, Farrell RJ, Kelly CP. Clostridium difficile. Gastroenterol Clin North Am 2001; 30:753-77.
2. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea. Arch Int Med 2001; 161:525-33.
3. Lyerly DM, Krivan HC, Wilkins TD. Clostridium difficile: Its disease and toxins. Clin Microbiol Rev 1988; 1:1-18.
4. Pothoulakis C, LaMont JT. Microbes and microbial toxins: paradigms for microbial mucosal interactions II. The integrated response of the intestine to Clostridium difficile toxins. Am J Physiol Gastrointest Liver Physiol 2001; 280:178-83.
5. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North Americ and Europe. Clin Microbiol Infect 2008; 12:2-18.
6. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, et al. Toxin B is essential for virulence of Clostridium difficile. Nature 2009; 458:1176-81.
7. Rupnik M. Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS Microbiol Rev 2008; 32:541-55.
8. Aktories K, Just I. Monoglucosylation of low-molecular-mass GTP-binding Rho proteins by clostridial cytotoxin. Trends Cell Biol 1995; 5:441-3.
9. Hofmann F, Busch C, Prepens U, Just I, Aktories K. Localization of the glucosyltransferase activity of Clostridium difficile toxin B to the N-terminal part of the holotoxin. J Biol Chem 1997; 272:11074-8.
10. Donelli G, Fiorentini C. Bacterial protein toxins acting on the cell cytoskeleton. New Microbiol 1994; 17:345-62.
11. 2+ plays a role in toxin A cell surface association. J Mol Biol 2005; 346:1197-206.
12. Von Eichel-Streiber C, Sauerborn M. Clostridium difficile toxin A carries a C-terminal repetitive structure homologous to the carbohydrate binding region of streptococcal glycosyltransferases. Gene 1990; 96:107-13.
13. Ho JG, Greco A, Rupnik M, Ng KK-S. Crystal structure of receptor-binding C-terminal repeats from Clostridium difficile toxin A. 2005.
14. García JL, Sánchez-Beato AR, Medrano FJ, López R. Versatility of Choline-Binding Domain. in: TA, (Ed.), Streptococcus pneumoniae, Mary Ann Liebert, Inc., New Rochelle 2000; 155-77.
15. Tucker KD, Wilkins TD. Toxin A of Clostridium difficile binds to the human carbohydrate antigens, I, X and Y. Infect Immun 1990; 59:73-8.
16. Krivan HC, Clark GF, Smith DF, Wilkins TD. Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Galá1-3Galâ1-4GlcNAc. Infect Immun 1986; 53:573-81.
17. Greco A, Ho JGS, Lin S-J, Palcic MM, Rupnik M, Ng KK. Carbohydrate recognition by Clostridium difficile toxin A. Nat Struct Mol Biol 2006; 13:460-1.
18. Brazier JS, Fawley W, Freeman J, Wilcox MH. Reduced susceptibility of Clostridium difficile to metronidazole. J Antimicrob Chemother 2001; 48:741-2.
19. Pelaez T, Alcala L, Alonso R, Rodriguez-Creixems M, Garcia-Lechuz JM, Bouza E. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2005; 46:1647-50.
20. McFarland LV. Alternative treatments for Clostridium difficile disease: what really works? J Med Microbiol 2005; 54:101-11.
21. Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987; 2:1519.
22. Chia JK, Chan SM, Goldstein H. Baker's yeast as adjunctive therapy for relapses of Clostridium difficile diarrhea. Clin Infect Dis 1995; 20:1581.
23. Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterol 1989; 96:981-8.
24. Palace GP, Lazari P, Norton K. Analysis of the physicochemical interactions between Clostridium difficile toxins and cholestyramine using liquid chromatography with post-column derivatization. Biochem Biophys Acta 2001; 1546:171-84.
25. Castagliuolo I, LaMont JT, Qiu B, Nikulasson ST, Pothoulakis C. A receptor decoy inhibits the enterotoxic effects of Clostridium difficile toxin A in rat ileum. Gastroenterol 1996; 111:433-8.
26. Kyne L, Warny M, Oamar A, Kelly CP. Asymptomatic carriage of Clostridium difficile. N Engl J Med 2000; 342:390-7.
27. Kyne L, Warny M, Oamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001; 357:189-93.
28. Aboudola S, Kotloff KL, Kyne L, Warny M, Kelly EC, Sougioultzis S, et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun 2003; 71:1608-10.
29. Giannasca PJ, Zhang ZX, Lei WD, Boden JA, Giel MA, Monath TP, et al. Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun 1999; 67:527-38.
30. Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 1998; 66:2018-25.
31. Lyerly DM, Bostwick EF, Binioin SB, Wilkins TD. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 1991; 59:2215-8.
32. Lyerly DM, Phelps CJ, Toth J, Wilkins TD. Characterization of toxins A and B of Clostridium difficile with monoclonal antibodies. Infect Immun 1986; 54:70-6.
33. Lyerly DM, Johnson JL, Frey SM, Wilkins TD. Vaccination against lethal enterocolitis with a nontoxic recombinant peptide of toxin A. Curr Microbiol 1990; 21:29-32.
34. Corthier G, Muller MC, Wilkins TD, Lyerly DM, L'Haridon R. Protection against experimental pseudomembranous colitis in gnotobiotic mice by use of monoclonal antibodies against Clostridium difficile toxin A. Infect Immun 1991; 59:1192-5.
35. Fernie DS, Thomson RO, Batty I, Walker PD. Active and passive immunization to protect against antibioticassociated caecitis in hamsters. Dev Biol Stand 1982; 53:325-32.
36. Lyerly DM, Phelps CJ, Wilkins TD. Monoclonal and specific polyclonal antibodies for immunoassay of Clostridium difficile toxin A. J Clin Microbiol 1985; 21:12-4.
37. Frey SM, Wilkins TD. Localization of two epitopes recognized by monoclonal antibody PCG-4 on Clostridium difficile toxin A. Infect Immun 1992; 60:2488-92.
38. Sauerborn M, Leukel P, von Eichel-Streiber C. The C-terminal ligand-binding domain of Clostridium difficile toxin A (TcdA) abrogates TcdA-specific binding to cells and prevents mouse lethality. FEMS Microbiol Lett 1997; 155:45-54.
39. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, et al. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 2006; 74:6339-47.
40. Marks JD. Deciphering antibody properties that lead to poten botulinum neurotoxin neutralization. Movement Disorders 2004; 19:101-8.
41. Volk WA, Bizzini B, Snyder RM, Bernhard E, Wagner RR. Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun 1984; 45:604-9.
42. Zwick MB, Wang M, Poignard P, Stiegler G, Katinger H, Burton DR, et al. Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies. J Virol 2001; 75:12198-208.
43. Wu C, Ying H, Grinnell C, Bryant S, Miller R, Clabbers A, et al. Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol 2007; 25:1290-7.
44. Michaelson JS, Demarest SJ, Miller B, Amatucci A, Synder WB, Wu X, et al. Anti-tumor activity of stability-engineered IgG-like bispecific antibodies targeting TRAIL-R2 and LTâR. mAbs 2009; 1:128-41.
45. Dimasi N, Gao C, Fleming R, Woods RM, Yao XT, Shirinian L, et al. The design and characterization of oligospecific antibodies for simultaneously targeting multiple disease mediators. J Mol Biol 2009; 393:672-92.
46. Wiberg FC, Rasmussen SK, Frandsen TP, Rasmussen LK, Tengbjerg K, Coljee VW, et al. Production of target-specific recombinant human polyclonal antibodies in mammalian cells. Biotechnol Bioeng 2006; 94:396-405.
47. Coloma MJ, Hastings A, Wims LA, Morrison SL. Novel vectors for the expression of antibody molecules using variable regions generated by polymerase chain reaction. J Immunol Methods 1992; 152:89-104.
48. Dattamajumdar AK, Jacobson DP, Hood LE, Osman GE. Rapid cloning of any rearranged mouse immunoglobulin variable genes. Immunogenetics 1996; 43:141-51.
49. Casimiro DR, Toy-Palmer A, Blake RC, Dyson HJ. Gene synthesis, high-level expression, and mutagenesis of Thiobacillus ferrooxidans rusticyanin: His 85 is a ligand to the blue copper center. Biochemistry 1995; 34:6640-8.
50. Day ES, Cachero TG, Qian F, Sun Y, Wen D, Pelletier M, et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 2005; 44:1919-31.
51. Doern A, Cao X, Sereno A, Reyes CL, Altshuler A, Huang F, et al. Characterization of inhibitory antiinsulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo. J Biol Chem 2009; 284:10254-67.